Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

被引:79
|
作者
Hamaoka, T. [2 ,3 ]
Costelloe, C. M. [4 ]
Madewell, J. E. [4 ]
Liu, P. [5 ]
Berry, D. A. [5 ]
Islam, R. [1 ]
Theriault, R. L. [1 ]
Hortobagyi, G. N. [1 ]
Ueno, N. T. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[3] St Lukes Int Hosp, Tokyo, Japan
[4] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
bone diseases; breast neoplasms; diagnostic imaging; response assessment; FDG-PET; THERAPY; SCAN; TOMOGRAPHY; CARCINOMA; DIAGNOSIS; ONCOLOGY;
D O I
10.1038/sj.bjc.6605546
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: We compared the utility of a new response classification (MDA; based on computed tomography (CT), magnetic resonance imaging (MRI), plain radiography (XR), and skeletal scintigraphy (SS)) and the World Health Organisation response classification (WHO; based on XR and SS) in stratifying breast cancer patients with bone-only metastases with respect to progression-free survival (PFS), overall survival (OS), and clinical response. METHODS: We retrospectively reviewed 41 patients with bone-only metastatic breast cancer and assigned responses according to the MDA and WHO criteria. We analysed whether the MDA or WHO response classifications correlated with PFS and OS. RESULTS: With the MDA criteria, there were significant differences in PFS between patients classified as responders and those classified as nonresponders (P = 0.025), but with the WHO criteria, there were not. Neither criteria distinguished responders from nonresponders in terms of OS. MDA response criteria correlated better than WHO response criteria with clinical response assessment. CONCLUSIONS: The MDA classification is superior to the WHO classification in differentiating between responders and nonresponders among breast cancer patients with bone-only metastases. Application of the MDA classification may allow bone lesions to be considered measurable disease. Prospective study is needed to test the MDA classification among patients with bone metastasis. British Journal of Cancer (2010) 102, 651-657. doi:10.1038/sj.bjc.6605546 www.bjcancer.com Published online 26 January 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:651 / 657
页数:7
相关论文
共 50 条
  • [31] Systemic T-cells demonstrate a tumour permissive response in breast cancer patients
    M. R. Kell
    J. Connelly
    D. C. Winter
    D. Beddy
    C. Canning
    R. W. G. Watson
    J. M. Fltzpatrick
    M. Kerin
    Irish Journal of Medical Science, 2002, 171 (Suppl 2)
  • [32] A PROSPECTIVE-STUDY OF ALTERNATIVE RESPONSE CRITERIA FOR BONE METASTASES FROM BREAST-CANCER
    COLEMAN, RE
    MASHITER, G
    WHITAKER, KB
    MOSS, DW
    FOGELMAN, IS
    RUBENS, RD
    BRITISH JOURNAL OF CANCER, 1986, 53 (03) : 431 - 431
  • [33] Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
    Mayte Delgado-Ureña
    Francisco G. Ortega
    Diego de Miguel-Pérez
    Alba Rodriguez-Martínez
    Jose L. García-Puche
    Hugh Ilyine
    Jose A. Lorente
    Jose Exposito-Hernandez
    M. Carmen Garrido-Navas
    Miguel Delgado-Ramirez
    M. José Serrano
    Journal of Translational Medicine, 16
  • [34] Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
    Delgado-Urena, Mayte
    Ortega, Francisco G.
    de Miguel-Perez, Diego
    Rodriguez-Martinez, Alba
    Garcia-Puche, Jose L.
    Ilyine, Hugh
    Lorente, Jose A.
    Exposito-Hernandez, Jose
    Carmen Garrido-Nayas, M.
    Delgado-Ramirez, Miguel
    Jose Serrano, M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [35] Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Rodriguez-Leal, Francisco Alejandro
    Haase, Rocco
    Thomas, Katja
    Eisele, Judith Christina
    Proschmann, Undine
    Schultheiss, Thorsten
    Kern, Raimar
    Ziemssen, Tjalf
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (10) : 1337 - 1346
  • [36] MONITORING THERAPY RESPONSE IN METASTATIC BREAST CANCER USING TUMOUR MARKERS CA15-3 AND TPS
    Sundquist, Marie
    Nilsson, Joakim
    Tejler, Goran
    BREAST, 2015, 24 : S46 - S46
  • [37] The tumour microenvironment influences long-term tamoxifen treatment response in breast cancer patients
    Romera, P. Camargo
    Romero, M. Rios
    Danielsson, O.
    Dar, H. Akhtar
    Lindstrom, L. S.
    Tobin, N. P.
    ANNALS OF ONCOLOGY, 2024, 35 : S327 - S327
  • [38] Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
    Heinemann, Volker
    Stintzing, Sebastian
    Modest, Dominik P.
    Giessen-Jung, Clemens
    Michl, Marlies
    Mansmann, Ulrich R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (14) : 1927 - 1936
  • [39] Targeted radiotherapy to the skeleton using 166HO-DOTMP with autologous stem cell transplantation for patients with bone-only metastatic breast cancer
    Champlin, RE
    Booser, D
    Rondon, G
    Williams, PA
    Wendt, R
    Hortobagyi, G
    Ueno, N
    Podoloff, D
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 84 - 85
  • [40] Evaluating tumour response to primary radiochemotherapy in breast cancer patients: what role for breast magnetic resonance imaging?
    Thibault, F.
    Bollet, M. A.
    Tardivon, A.
    Malhaire, C.
    Zemmour-Elfersi, G.
    BREAST CANCER RESEARCH, 2008, 10 (Suppl 3)